ClinicalTrials.gg
RecruitingNCT06994507Updated Aug 6, 2025

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

A Phase 3 interventional study of GM1 and Placebo in Chemotherapy-induced Peripheral Neuropathy (CIPN), sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with Albumin-paclitaxel chemotherapy regimen.

Read the detailed description

This study was randomly divided into two groups at a ratio of 1:1, with 176 subjects in each group. All patients received GM1/ placebo treatment + chemotherapy.

The main purpose of this study is to evaluate the effectiveness of GM1 in preventing peripheral neuropathy caused by albumin-paclitaxel chemotherapy. The primary endpoint was the end of GM1 treatment in cycle 4 (C4D21), and the proportion of patients whose FACT/GOG-Ntx score changed by more than 12 points from baseline.

02

Conditions studied

  • Chemotherapy-induced Peripheral Neuropathy (CIPN)
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign the form;
  • Age: 18 to 75 years old;
  • Female patients with breast cancer confirmed byhistological and/or cytological diagnostic basis for breast cancer and are intended to receive /neoadjuvant therapy with Albumin paclitaxel regimens;
  • : 0-1
  • Adequate organ function level
  • (HbA1c) \< 7.0%;
  • For women of : use effective measures for contraception from the date of signing the informed consent form until 30 days after the last use of the investigatory drug.
  • Patients can accurately record or express the occurrence and severity of peripheral neuropathy through questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Grade ≥1 peripheral neuropathy ( grade ≥1) or any of the first 4 items of FACT/GOG-Ntx ≥1;
  • There are risk factors for peripheral neuropathy (excluding peripheral neuropathy caused by chemotherapy).
  • History of another malignant tumors (except breast cancer)
  • Symptoms such as muscle pain in the limbs that interfere with the evaluate of peripheral neuropathy;
  • Uncontrolled cardiovascular and cerebrovascular system diseases or hypertension
  • Active infections that require systematic treatment, including bacteria, fungi or viruses, within one week before first study drug use; Or infectious diarrhea occurred within 4 weeks before the first study drug use;
  • Hereditary abnormal glycolipid metabolism, infection or known Acquired Immune Deficiency Syndrome (AIDS); Positive syphilis antibody, active , active
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
352 participants (estimated)

Study arms

  • Experimental
    GM1 400mg

    Albumin-paclitaxel was administered on Day 1 of each cycle, Q3W. GM1 is administered with D-1,D1,D2 every cycle

    Drug: GM1

  • Placebo comparator
    Placebo

    Albumin-paclitaxel was administered on Day 1 of each cycle, Q3W. Placebo is administered with D-1,D1,D2 every cycle

    Drug: Placebo

Interventions

  • DrugG(M1) GangliosideStudies of G(M1) GangliosideG(M1) Ganglioside pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GM1 was administered intravenously one day before the administration of each cycle of chemotherapy. The experimental group was given 400 mg of GM1 injection. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.

  • DrugPlacebo

    Placebo was administered intravenously one day before the administration of each cycle of chemotherapy. The control group was given placebo. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.

06

What researchers measure

Primary outcomes

  1. FACT/GOG-Ntx scores with a change of more than 12 points from the baseline

    The proportion of those whose FACT/GOG-Ntx score changed by more than 12 points from the baseline at the end of the fourth cycle of treatment

    Time frame: At the end of Cycle 4 (21day/Cycle)

Secondary outcomes

  1. The incidence of grade ≥2 (CTCAE) CIPN

    The incidence of grade ≥2 (CTCAE) CIPN

    Time frame: At the end of Cycle 4 (21day/Cycle),At the end of Cycle 6 (21day/Cycle)

  2. Assessment of functional impairment

    Vibration sensitivity test and Grooved pegboard test

    Time frame: At the end of Cycle 4 (21day/Cycle),At the end of Cycle 6 (21day/Cycle)

  3. Assessment of Quality of Life

    Assessment of Quality of Life(QLQ C30)

    Time frame: At the end of Cycle 4 (21day/Cycle),At the end of Cycle 6 (21day/Cycle)

  4. FACT/GOG-Ntx scores with a change of more than 12 points from the baseline

    The proportion of those whose FACT/GOG-Ntx score changed by more than 12 points from the baseline at the end of the sixth cycle of treatment

    Time frame: At the end of Cycle 6 (21day/Cycle)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Sep 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 29, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Jun 2027
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06994507
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Aug 1, 2025
Primary completion
Sep 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 6, 2025

Study contacts

ZeFei Jiang, Chief Physician
Contact
jzf_cscobc@csco.org.cn
010-66947175

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: G(M1) Ganglioside

Start the discussion